{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["John BV"],"funding":["NCATS NIH HHS","NCI NIH HHS","Division of Cancer Prevention, National Cancer Institute"],"pagination":["384-393"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8810619"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["42(2)"],"pubmed_abstract":["<h4>Background</h4>The natural history of patients with anti-mitochondrial antibody (AMA)-negative Primary Biliary Cholangitis (PBC) cirrhosis has not been well defined, with prior studies showing discordant results. Furthermore, most studies of AMA-negative PBC have limited numbers of patients with cirrhosis and liver-related outcomes.<h4>Methods</h4>We investigated the association of AMA-negative PBC and the development of death, liver-related death, decompensation and hepatocellular carcinoma (HCC), in a large cohort of predominantly male patients with PBC cirrhosis assembled from the Veterans Health Administration.<h4>Results</h4>In a cohort of 521 patients with PBC cirrhosis (65 AMA-negative) with a total follow-up of 2504.3 person-years (PY) from cirrhosis diagnosis, patients with AM"],"journal":["Liver international : official journal of the International Association for the Study of the Liver"],"pubmed_title":["Rates of decompensation, hepatocellular carcinoma and mortality in AMA-negative primary biliary cholangitis cirrhosis."],"pmcid":["PMC8810619"],"funding_grant_id":["UL1 TR001863","P30 CA016059"],"pubmed_authors":["Dahman B","Khakoo NS","Levy C","John BV","Taddei TH","Deng Y","Kaplan DE"],"additional_accession":[]},"is_claimable":false,"name":"Rates of decompensation, hepatocellular carcinoma and mortality in AMA-negative primary biliary cholangitis cirrhosis.","description":"<h4>Background</h4>The natural history of patients with anti-mitochondrial antibody (AMA)-negative Primary Biliary Cholangitis (PBC) cirrhosis has not been well defined, with prior studies showing discordant results. Furthermore, most studies of AMA-negative PBC have limited numbers of patients with cirrhosis and liver-related outcomes.<h4>Methods</h4>We investigated the association of AMA-negative PBC and the development of death, liver-related death, decompensation and hepatocellular carcinoma (HCC), in a large cohort of predominantly male patients with PBC cirrhosis assembled from the Veterans Health Administration.<h4>Results</h4>In a cohort of 521 patients with PBC cirrhosis (65 AMA-negative) with a total follow-up of 2504.3 person-years (PY) from cirrhosis diagnosis, patients with AM","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Feb","modification":"2025-04-21T15:51:15.992Z","creation":"2025-04-21T15:51:15.992Z"},"accession":"S-EPMC8810619","cross_references":{"pubmed":["34614294"],"doi":["10.1111/liv.15079"]}}